Istradefylline
- Generic Name
- Istradefylline
- Brand Names
- Nourianz
- Drug Type
- Small Molecule
- Chemical Formula
- C20H24N4O4
- CAS Number
- 155270-99-8
- Unique Ingredient Identifier
- 2GZ0LIK7T4
Overview
Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A receptors in the basal ganglia. This region of the brain is highly involved in motor control. Istradefylline is indicated as an adjunct treatment to levodopa and carbidopa for Parkinson's disease. This drug was first approved in Japan on 25 March 2013. Istradefylline was granted FDA approval on 27 August 2019.
Background
Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A receptors in the basal ganglia. This region of the brain is highly involved in motor control. Istradefylline is indicated as an adjunct treatment to levodopa and carbidopa for Parkinson's disease. This drug was first approved in Japan on 25 March 2013. Istradefylline was granted FDA approval on 27 August 2019.
Indication
Istradefylline is indicated in adjunct to levodopa and carbidopa in the treatment of Parkinson's disease.
Associated Conditions
- Parkinson's Disease (PD)
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.